Management Presentation: Biosimilar Pipeline and Margin Improvement Strategy

Attractive market fundamentals | Leadership and scale | Multiple growth drivers Margin improvement | Attractive financial outlook | Compelling sustainability story B Significant opportunity to further rationalize the network Planned network efficiencies Internal manufacturing sites 18 Current 2023 15 Future 20251 External manufacturing sites² -700 Current 2023 ~350 Future 2027 Network design objectives Improve capital allocation Increase asset efficiency Optimize make-or-buy decisions Invest in cost efficient sites Modernize 1. After announced closures; 2. External finished drugs and API supplier sites. 20 Management Presentation Concentrate external spend Support our launch strategy SANDOZ

View entire presentation